Delaware Supreme Court sides with Zantac drugmakers over evidence
ReutersJul 10, 2025 7:56 PM
July 10 (Reuters) - Delaware's highest court ruled on Thursday that patients suing drugmakers GSK GSK.L, Pfizer PFE.N, Sanofi SASY.PA and Boehringer Ingelheim cannot introduce reports from several experts to support their claim that the heartburn drug Zantac causes cancer.
The decision by the Delaware Supreme Court is a victory for the drugmakers, in a case closely watched by business groups that fear an adverse outcome could erode Delaware's reputation as a business safe haven by encouraging mass tort litigation.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
Investing in Energy Stocks
TradingKey - When investors consider investing in energy, they think about oil wells and pumping gasoline. But the 2025 storyline is bigger, and stealthier. Energy today is as much about geopolitics and climate policy as about barrels and pipelines, about massive shifts in the way the world...TradingKey
20 hours ago
.jpg)
Q2 2025 Earnings Season Preview: The First Test Under Trump’s Tariffs — Could Low Expectations Bring Surprises?
TradingKey - Mid-July will mark the first earnings season since President Donald Trump’s tariff policy took effect, offering investors a glimpse into how American companies are handling the impact of trade tensions. Analysts believe that with low expectations heading into Q2, it may be easier forTradingKey
Wed, Jul 9
Prediction! Federal Reserve Chairman Jerome Powell's Next Move Will Be an Interest Rate Cut
The Federal Reserve must balance the risks of higher inflation with the risks of higher unemployment when making decisions on interest rates.Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »*Stock prices used were..The Motley Fool
Thu, Jun 26
What is the Future of Stablecoins? Here are Some Stablecoin Stocks to Watch
With regulations solidifying, institutional money flowing in, and global market expansion accelerating, stablecoin-related stocks could experience unprecedented growth.TradingKey
Wed, Jun 11
What Is the GENIUS Act, and Why Is Its Impact Comparable to a Bitcoin Spot ETF?
The GENIUS Act represents a groundbreaking federal regulatory framework for U.S. stablecoins, defining legal issuance standards, oversight responsibilities, consumer protections, and reserve requirements. While its primary objective is to advance U.S. financial interests, it will significantly shaTradingKey
Fri, May 30
Tradingkey
